Table 1.
Demographic and clinical characteristics of the study populations.
| Characteristics | HC | OA | RA | P |
|---|---|---|---|---|
| Demographic | ||||
| Number of subjects | 69 | 8 | 71 | |
| Female/Male a | 47 /22 | 6 /2 | 52 /19 | 0.78 |
| Age (mean±SD years) a | 50.7±4.2 | 53.7±2.4 | 51.9±3.1 | 0.29 |
| Disease status | ||||
| Disease duration (mean±SD years) | N/A | 7.5±1.8 | ||
| Active disease | N/A | 86.1 % | ||
| Tobacco use | N/A | 15.2% | ||
| Extra-articular manifestations | N/A | 43.5% | ||
| ESR, mm/h | N/A | 37.9±3.1 | ||
| DAS28-CRP (mean±SD) | N/A | 3.6±0.4 | ||
| DMARD naïve | N/A | 11.1% | ||
| Radiographic status | ||||
| Total modified Sharp score (mean±SD) | 24.7±19.4 | |||
| Joint erosion subscore (mean±SD) | 17.2±18.6 | |||
| Medications | ||||
| Corticosteroids | N/A | 70.8% | ||
| Methotrexate | N/A | 66.7% | ||
| Hydroxychloroquine | N/A | 56.9% | ||
| Leflunomide | N/A | 25.0% | ||
| TNF-α inhibitors | N/A | 12.5% |
a
No significant difference, RA patients compared with HC donors.
ESR, erythrocyte sedimentation rate; DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drugs; an active disease defined by Food and Drug Administration (FDA) criteria [presence of three or more of the following: morning stiffness (> 45 min), swollen joints (> 3), tender joints (> 6) and sedimentation rate (> 20 mm/h)].
N/A, Not Applicable.